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Brilaroxazine
The current psychopharmacological treat-
ment of  schizophrenia, which involves both 
typical and atypical antipsychotics, is often 
cumbersome in terms of  tolerance difficul-
ties. Those occur because of  frequent side ef-
fects that lead to limited adherence and effec-
tiveness. Furthermore, antipsychotics do not 
provide a wide range of  efficacy in different 
symptom classes so it is no surprise that up 
to 30 % of  patients are refractory to the cur-
rent treatment. This leads to the conclusion 
that critical necessities are often unmet in 
treatment of  schizophrenia. 
Brilaroxazine (RP5063, also known as 
RP5000) is an atypical antipsychotic in re-
search and development under the auspices 
of  Reviva Pharmaceuticals. It is considered 
to be a modulator of  the dopamine-sero-
tonin system, which has a pronounced affin-
ity for a number of  receptors of  the sero-
tonin and dopamine system. It is structurally 
similar to cariprazine, brexpiprazole, and 
in particular to aripiprazole. Studies have 
shown that it has a high affinity for D2/3/4 
and 5-HT1A/2A/2B/2C/6/7 receptors and a mod-
erate affinity for the serotonin transporter. 
It demonstrated activity of  a partial agonist 
on dopamine D2, D3, D4 receptors, and se-
rotonin 5-HT1A and 5-HT2A receptors with 
antagonistic activity on serotonin 5-HT2B, 
5-HT6 and 5-HT7 receptors. Initial clinical 
experience in healthy volunteers and patients 
with schizophrenia and schizoaffective disor-
der define this molecule as a promising addi-
tion to current psychopharmacological mo-
dalities. Pharmacokinetics of  brilaroxazine 
proved to be very predictable and consistent. 
We would emphasize its relatively rapid oral 
absorption, linear, dose-dependent increase 
in maximum concentration, lack of  excess 
accumulation and long half-life of  over 40 
hours, which altogether lead to simple dosing 
and administration once a day. It is believed 
that the balance between antagonism and ag-
onism on the dopamine and serotonin system 
underlies its stabilizing effect and contributes 
to the lower incidence of  side effects related 
to the use of  already available antipsychotics. 
During Phase I and II of  clinical trials, it did 
not cause cardiometabolic, cardiovascular, 
neurological, or endocrinological side effects 
that would complicate ongoing treatment. 
Brilaroxazine has so far proven effective in 
studies of  patients with acute-phase schizo-
phrenia. Namely, during placebo-controlled 
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phase II of  clinical trials it showed signifi-
cance when compared to placebo in the total 
PANSS score on day 28 matched to baseline. 
It was also investigated in animal models of  
psychosis and episodic memory in mice and 
had a significant effect on subchronic phen-
cyclidine-induced damage of  novel objects 
recognition which is used as a correlate of  
episodic memory, but did not affect reverse 
learning which is used as a correlate of  ex-
ecutive functions. Its administration signifi-
cantly increases the release of  cortical dopa-
mine, which may be crucial for some of  its 
pro-cognitive properties. These results indi-
cate that brilaroxazine, alone or as an adjunct 
treatment, has multiple bases for improving 
some of  the cognitive deficits associated with 
schizophrenia. The molecule is currently in 
phase III of  clinical trials as a potential drug 
for the treatment of  schizophrenia and is also 
being investigated as treatment for bipolar 
affective disorder, major depressive episode, 
psychosis/agitation in Alzheimer’s dementia, 
psychotic conditions in Parkinson’s disease, 
attention deficit and hyperactivity disorder 
and autism.
In regard to indications outside the do-
main of  psychiatric and neurological diseases, 
brilaroxazine has demonstrated the potential 
for treatment of  pulmonary arterial hyper-
tension and idiopathic pulmonary fibrosis. 
There is evidence that it prevents monocro-
taline-induced pulmonary hypertension in 
rats, which can be explained by the fact that 
regulation of  serotonin 5-HT2A and 5-HT2B 
receptors is impaired in the pulmonary arte-
rial hypertension, a disease characterized by 
remodeling and constriction of  the pulmo-
nary vasculature. An attempt was made to 
prove the benefits of  the molecule using the 
above animal model, and it was found that 
it reduces pulmonary vascular pathology and 
optimizes hemodynamics by acting on right 
ventricular pressure, right ventricular hyper-
trophy, saturation of  systemic  blood with 
oxygen, and overall rat health. Also, the drug 
has shown strong efficacy in highly investi-
gated translational animal models that have 
been shown to mimic pulmonary fibrosis 
in humans, significantly improving survival 
rates and reducing concentration of  inflam-
matory cytokines and lung fibrosis. The US 
Food and Drug Administration has awarded 
it the status of  the so-called orphan drug for 
these diseases, given its potential for clinically 
significant improvement and stabilization of  
pulmonary function. 
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Figure 1. Three-dimensional chemical structure of  brilaroxazine. 
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